Search
for
Sort by
Research 181–210 of 1000+
- Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science
- Off-Label Use of Topical Minoxidil in Alopecia: A Review
- Off-Label Uses of Topical Vitamin D in Dermatology: A Systematic Review
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Controversies in off‐label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies
- Off-label uses of retinoids in dermatology
- Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art
- Off-label prescriptions: patient safety first
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Entrepreneurship in Off-Label Drug Prescription: Just What the Doctor Ordered!
- Off-label dermatologic uses of IL-23 inhibitors
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Off-label Prescription and Challenges in Clinical Practice: An Abridged Review
- Off Label Medication and Use of Unapproved Drugs
- Botulinum Toxin Off-Label Use in Dermatology: A Review
- Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review
- The pattern of off-label and unlicensed drug use in adult and pediatric patients in the Kingdom of Saudi Arabia: multicenter retrospective study
- 13777 The off-label use of spironolactone in female pattern hair loss
- Beyond Minoxidil: Evidence-Based Off-Label Therapies for Male Androgenetic Alopecia
- Review of Promising Off-Label Use of Deucravacitinib
- Evidence for the off-label use of tofacitinib in alopecia areata
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- Dupilumab: A Review of Present Indications and Off-Label Uses
- Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations
- Deucravacitinib in dermatology: current indication and existing off-label data
- Tacrolimus ointment: summarizing two decades of experience in off-label use. Use in rosacea, seborrheic dermatitis, papulosquamous dermatoses, lupus erythematosus, eczematous dermatoses, alopecia, and other diseases
- Facial hair enhancement with minoxidil—an off-label use
- (423) A Case Series of Successful Off-label Use of Flibanserin
- 498 Efficacy of photobiomodulation therapy for the off-label treatment of alopecia in skin types V-VI
- FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire/Function in Women